{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06011798",
            "orgStudyIdInfo": {
                "id": "UBX1325-04"
            },
            "organization": {
                "fullName": "Unity Biotechnology, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)",
            "officialTitle": "A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With Diabetic Macular Edema",
            "therapeuticArea": [
                "Other",
                "Endocrinology",
                "Ophthalmology"
            ],
            "study": "assess-the-efficacy-and-safety-of-repeat-intravitreal-injections-of-foselutoclax-in-patients-with-dme-aspire"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-08-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-02",
            "studyFirstSubmitQcDate": "2023-08-23",
            "studyFirstPostDateStruct": {
                "date": "2023-08-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-07",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Unity Biotechnology, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema. The main questions the study aims to answer are:\n\n* Assess the efficacy of foselutoclax compared to aflibercept\n* Assess the safety and tolerability of foselutoclax",
            "detailedDescription": "This study is intended to assess the efficacy and safety of foselutoclax, a phosphate pro-drug, and its active parent molecule (UBX0601, a BCL-xL inhibitor) following repeat intravitreal (IVT) injections of foselutoclax in patients with Diabetic Macular Edema (DME).\n\nApproximately 50 patients will be enrolled and randomized 1:1 into either the foselutoclax arm,10 \u03bcg given 8 weeks apart, or the control arm of aflibercept, 2 mg every 8 weeks in order to assess the primary objective. All patients will be followed for approximately 36 weeks.\n\nThe injector will be unmasked but the evaluator will remain masked throughout the study.\n\nThis study will enroll participants \u226518 years of age with active DME disease despite treatment, with best corrected visual acuity (BCVA) between 70 to 30 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (equivalent to 20/40 to 20/250 on the Snellen chart). Once patients meet inclusion/exclusion criteria, patients will receive 3 run-in injections of aflibercept approximately 4 weeks apart, with the last aflibercept injection 4-6 weeks prior to Day 1."
        },
        "conditionsModule": {
            "conditions": [
                "Diabetic Macular Edema",
                "Retinal Disease",
                "Macular Edema",
                "Diabetes Mellitus",
                "Diabetic Retinopathy",
                "Retinal Degeneration",
                "Retinal Diseases",
                "Eye Diseases",
                "Edema"
            ],
            "keywords": [
                "DME"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 50,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Anti-VEGF control arm",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Prior to randomization, participants will receive 3 IVT injections of aflibercept over 4-week intervals. Upon randomization, participants will receive 2 mg aflibercept (50 \u03bcl of 40 \u03bcg/\u03bcl solution) IVT on Day 1, Weeks 8, and 16. A sham procedure will also be administered on Day 1.",
                    "interventionNames": [
                        "Drug: Aflibercept"
                    ]
                },
                {
                    "label": "foselutoclax arm",
                    "type": "EXPERIMENTAL",
                    "description": "Prior to randomization, participants will receive 3 IVT injections of aflibercept over 4-week intervals. Upon randomization, participants will receive 10 \u03bcg foselutoclax (50 \u03bcl of 0.2 \u03bcg/\u03bcl solution) IVT on Day 1 and Weeks 8 and 16. 2 mg aflibercept (50 \u03bcl of 40 \u03bcg/\u03bcl solution) will also be administered on Day 1.",
                    "interventionNames": [
                        "Drug: Aflibercept",
                        "Drug: foselutoclax"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Aflibercept",
                    "description": "Anti-VEGF control",
                    "armGroupLabels": [
                        "Anti-VEGF control arm",
                        "foselutoclax arm"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "foselutoclax",
                    "description": "Experimental drug",
                    "armGroupLabels": [
                        "foselutoclax arm"
                    ],
                    "otherNames": [
                        "UBX1325"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Mean change from baseline in BCVA by ETDRS letter",
                    "description": "Mean change from baseline in Best-Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letter",
                    "timeFrame": "24 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Assess other efficacy outcome - Changes in BCVA",
                    "description": "Changes in BCVA (ETDRS letters) from baseline to each visit through Week 36",
                    "timeFrame": "24 and 36 weeks"
                },
                {
                    "measure": "Assess other efficacy outcome - Changes in CST",
                    "description": "Change in Central Subfield Thickness (CST) as measured in microns from baseline to each visit through Week 36",
                    "timeFrame": "24 and 36 weeks"
                },
                {
                    "measure": "Assess other efficacy outcome - ETDRS gains",
                    "description": "Proportion of participants gaining \u226515, \u226510, \u22655, or \u22650 ETDRS letters in BCVA from baseline in the Study Eye (SE) to Week 36",
                    "timeFrame": "24 and 36 weeks"
                },
                {
                    "measure": "Assess other efficacy outcome - Rescue metrics",
                    "description": "Proportion of participants who do not require rescue",
                    "timeFrame": "24 and 36 weeks"
                },
                {
                    "measure": "Assess safety outcome - TEAE",
                    "description": "Percentage of participants with at least one treatment-emergent ocular adverse event (AE) in the SE or Fellow Eye (FE)",
                    "timeFrame": "24 and 36 weeks"
                },
                {
                    "measure": "Assess other efficacy outcome - Changes in BCVA",
                    "description": "Changes in BCVA from baseline to last observation at or prior to Week 36",
                    "timeFrame": "24 and 36 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients aged \u226518 years.\n* Patients with nonproliferative DR and DME\n* Center-involved DME with Central Subfield Thickness (CST) \u2265325-900 \u03bcm\n* BCVA in the SE (most affected) of 70 to 30 ETDRS letters (equivalent to 20/40 to 20/250 on the Snellen chart)\n\nExclusion Criteria:\n\n* Concurrent disease in the study eye (SE) or structural damage, other than DME, that could compromise BCVA, prevent BCVA improvement, require medical or surgical intervention during the study period, confound interpretation of the results, or interfere with assessment of toxicity or Color Fundus Photography (CFP) in the SE.\n* Significant media opacities, including cataract, or posterior capsule opacification, which might interfere with VA, assessment of toxicity, or fundus imaging in either eye.\n* Any medical condition that is uncontrolled and may prevent participation in this study, as determined by the Investigator or disqualify individuals from enrollment.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sharon Klier, MD, MPH",
                    "role": "CONTACT",
                    "phone": "650-513-0096",
                    "email": "UBX1325_medicalmonitor@unitybiotechnology.com"
                },
                {
                    "name": "Clinical Operations",
                    "role": "CONTACT",
                    "phone": "650-513-0096",
                    "email": "clinops@unitybiotechnology.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Sharon Klier, MD, MPH",
                    "affiliation": "Unity Biotechnology, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "California Retina Consultants",
                    "status": "RECRUITING",
                    "city": "Bakersfield",
                    "state": "California",
                    "zip": "93309",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.37329,
                        "lon": -119.01871
                    }
                },
                {
                    "facility": "Retina-Vitreous Associates Medical Group",
                    "status": "RECRUITING",
                    "city": "Beverly Hills",
                    "state": "California",
                    "zip": "90211",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.07362,
                        "lon": -118.40036
                    }
                },
                {
                    "facility": "Salehi Retina Institute Inc.",
                    "status": "RECRUITING",
                    "city": "Huntington Beach",
                    "state": "California",
                    "zip": "92647",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.6603,
                        "lon": -117.99923
                    }
                },
                {
                    "facility": "Bay Area Retina Associates",
                    "status": "RECRUITING",
                    "city": "Walnut Creek",
                    "state": "California",
                    "zip": "94598",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.90631,
                        "lon": -122.06496
                    }
                },
                {
                    "facility": "Advanced Vision Research Institute",
                    "status": "RECRUITING",
                    "city": "Longmont",
                    "state": "Colorado",
                    "zip": "80503",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.16721,
                        "lon": -105.10193
                    }
                },
                {
                    "facility": "Rand Eye Institute",
                    "status": "RECRUITING",
                    "city": "Deerfield Beach",
                    "state": "Florida",
                    "zip": "33064",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 26.31841,
                        "lon": -80.09977
                    }
                },
                {
                    "facility": "Florida Eye Associates",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "state": "Florida",
                    "zip": "32901",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.08363,
                        "lon": -80.60811
                    }
                },
                {
                    "facility": "Retina Vitreous Associates of Florida",
                    "status": "RECRUITING",
                    "city": "Saint Petersburg",
                    "state": "Florida",
                    "zip": "33711",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.77086,
                        "lon": -82.67927
                    }
                },
                {
                    "facility": "University Retina and Macula Associates",
                    "status": "RECRUITING",
                    "city": "Lemont",
                    "state": "Illinois",
                    "zip": "60439",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.67364,
                        "lon": -88.00173
                    }
                },
                {
                    "facility": "Midwest Eye",
                    "status": "RECRUITING",
                    "city": "Carmel",
                    "state": "Indiana",
                    "zip": "46290",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.97837,
                        "lon": -86.11804
                    }
                },
                {
                    "facility": "Cumberland Valley Retina Consultants",
                    "status": "RECRUITING",
                    "city": "Hagerstown",
                    "state": "Maryland",
                    "zip": "21740",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.64176,
                        "lon": -77.71999
                    }
                },
                {
                    "facility": "Deep Blue Retina Clinical Research, PLLC",
                    "status": "RECRUITING",
                    "city": "Southaven",
                    "state": "Mississippi",
                    "zip": "38671",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.98898,
                        "lon": -90.01259
                    }
                },
                {
                    "facility": "Sierra Eye Associates",
                    "status": "RECRUITING",
                    "city": "Reno",
                    "state": "Nevada",
                    "zip": "89502",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.52963,
                        "lon": -119.8138
                    }
                },
                {
                    "facility": "Envision Ocular, LLC",
                    "status": "RECRUITING",
                    "city": "Bloomfield",
                    "state": "New Jersey",
                    "zip": "07003",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.80677,
                        "lon": -74.18542
                    }
                },
                {
                    "facility": "EyeHealth Northwest",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97225",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Erie Retina Research, LLC",
                    "status": "RECRUITING",
                    "city": "Erie",
                    "state": "Pennsylvania",
                    "zip": "16507",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.12922,
                        "lon": -80.08506
                    }
                },
                {
                    "facility": "Vision Research Solutions, PLLC",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19141",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Retina Consultants of Carolina",
                    "status": "RECRUITING",
                    "city": "Greenville",
                    "state": "South Carolina",
                    "zip": "29605",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.85262,
                        "lon": -82.39401
                    }
                },
                {
                    "facility": "Retina Research Institution of Texas",
                    "status": "RECRUITING",
                    "city": "Abilene",
                    "state": "Texas",
                    "zip": "79606",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.44874,
                        "lon": -99.73314
                    }
                },
                {
                    "facility": "Austin Retina Associates",
                    "status": "RECRUITING",
                    "city": "Round Rock",
                    "state": "Texas",
                    "zip": "78681",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.50826,
                        "lon": -97.6789
                    }
                },
                {
                    "facility": "Retina Center of Texas",
                    "status": "RECRUITING",
                    "city": "Southlake",
                    "state": "Texas",
                    "zip": "76092",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.94124,
                        "lon": -97.13418
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008269",
                    "term": "Macular Edema"
                },
                {
                    "id": "D000012164",
                    "term": "Retinal Diseases"
                },
                {
                    "id": "D000003930",
                    "term": "Diabetic Retinopathy"
                },
                {
                    "id": "D000005128",
                    "term": "Eye Diseases"
                },
                {
                    "id": "D000012162",
                    "term": "Retinal Degeneration"
                },
                {
                    "id": "D000004487",
                    "term": "Edema"
                }
            ],
            "ancestors": [
                {
                    "id": "D000008268",
                    "term": "Macular Degeneration"
                },
                {
                    "id": "D000003925",
                    "term": "Diabetic Angiopathies"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000048909",
                    "term": "Diabetes Complications"
                },
                {
                    "id": "D000003920",
                    "term": "Diabetes Mellitus"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000015785",
                    "term": "Eye Diseases, Hereditary"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M8271",
                    "name": "Eye Diseases",
                    "asFound": "Eye Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "relevance": "LOW"
                },
                {
                    "id": "M14999",
                    "name": "Retinal Diseases",
                    "asFound": "Retinal Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7657",
                    "name": "Edema",
                    "asFound": "Edema",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11261",
                    "name": "Macular Edema",
                    "asFound": "Macular Edema",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7125",
                    "name": "Diabetic Retinopathy",
                    "asFound": "Diabetic Retinopathy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14997",
                    "name": "Retinal Degeneration",
                    "asFound": "Retinal Degeneration",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11260",
                    "name": "Macular Degeneration",
                    "relevance": "LOW"
                },
                {
                    "id": "M7120",
                    "name": "Diabetic Angiopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M26004",
                    "name": "Diabetes Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M18339",
                    "name": "Eye Diseases, Hereditary",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC11",
                    "name": "Eye Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000533178",
                    "term": "Aflibercept"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020533",
                    "term": "Angiogenesis Inhibitors"
                },
                {
                    "id": "D000043924",
                    "term": "Angiogenesis Modulating Agents"
                },
                {
                    "id": "D000006133",
                    "term": "Growth Substances"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000006131",
                    "term": "Growth Inhibitors"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M257727",
                    "name": "Aflibercept",
                    "asFound": "DNA",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22318",
                    "name": "Angiogenesis Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M9231",
                    "name": "Growth Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}